This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Deutsches Krebsforschungszentrum. Active years: 2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016
Title: Monika Frank-Stohr: Innovator in Oncolytic Virotherapy
Introduction
Monika Frank-Stohr is a notable inventor based in Germany, recognized for her contributions to the field of oncolytic virotherapy. Her innovative work focuses on the treatment of mesenchymal tumors, particularly malignant bone tumors such as osteosarcoma and Ewing's sarcoma.
Latest Patents
Monika Frank-Stohr holds a significant patent titled "Oncolytic Virotherapy For The Therapy Of Sarcoma." This patent describes the use of a replication competent parvovirus, specifically H-1PV, for the treatment of localized and metastasized bone tumors. Despite having 1 patents, her research has the potential to impact cancer therapy significantly.
Career Highlights
Throughout her career, Monika has focused on developing innovative therapeutic strategies that leverage the unique properties of viruses to target cancer cells. Her work is at the forefront of cancer research, aiming to provide new hope for patients suffering from aggressive forms of cancer.
Collaborations
Monika has collaborated with esteemed colleagues, including Zoltan Kis and Jeaninne Lacroix, to advance her research in oncolytic virotherapy. Their combined expertise enhances the potential for breakthroughs in cancer treatment.
Conclusion
Monika Frank-Stohr's pioneering work in oncolytic virotherapy exemplifies the innovative spirit of modern science. Her research holds promise for developing effective treatments for challenging cancers, paving the way for future advancements in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile